WP
MLYS icon

Woodline Partners’s Mineralys Therapeutics MLYS Stock Holding History

Woodline Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-87,868
Closed -$1.19M – 990
2025
Q2 		$1.19M Buy
87,868
+40,206
+84% +$583K 0.01% 788
2025
Q1 		$757K Buy
+47,662
New +$548K ﹤0.01% 790
2024
Q1 		– Sell
-175,000
Closed -$1.5M – 594
2023
Q4 		$1.5M Hold
175,000
– – 0.02% 392
2023
Q3 		$1.66M Hold
175,000
– – 0.02% 413
2023
Q2 		$2.98M Hold
175,000
– – 0.04% 373
2023
Q1 		$2.74M Buy
+175,000
New +$2.95M 0.04% 381

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners's MLYS Position: Q3 2025 in Review

Woodline Partners sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 87,868 shares — an estimated $1.19M sold.

Woodline Partners first reported a position in MLYS in Q1 2023 and held it in 6 quarters. The position peaked at $2.98M in Q2 2023. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • Woodline Partners reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 87,868 Mineralys Therapeutics shares in Q3 2025, an estimated $1.19M.
  • Woodline Partners first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 6 quarters.
  • Woodline Partners's Mineralys Therapeutics position peaked at $2.98M in Q2 2023.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.